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The Possible Impact of Legal Globalization on
the ECJ Decision on Human Embryonic Stem
Cell Patents and its Implications
Amy LA*

I.

Introduction: From Briistle to ISCC

On December 18, 2014, the Grand Chamber of the Court of Justice of the
European Union (ECJ) lifted part of its more general 2011 ban on obtaining
patents for human embryonic stem cells (hESCs), by ruling in International
Stem Cell Corporation v. Comptroller General of Patents, Designs and Trade
Marks (ISCC) that hESCs made from unfertilized eggs can be patented.' In
this landmark case, the ECJ held that the moral exclusion of industrial and
commercial uses of "human embryos" in Article 6(2)(c) in Directive 98/44/
EC on the legal protection of biotechnological inventions, or the Biotech
Directive, does not cover "parthenotes," the unfertilized human eggs
produced by parthenogenesis.2
This case arose when the United Kingdom's Intellectual Property Office
(UKIPO) refused to grant two national patents to International Stem Cell
Corporation (ISCC), a California-based publicly traded biotech company.
The UKIPO stated that these two patents growing out of parthenogenesis
fell within the definition of the term "human embryo" adopted by the Grand
Chamber in Brzistle v. Greenpeace.3 ISCC appealed, arguing that Brustle did
not apply because mammalian parthenotes can never develop to term due to
a lack of paternal DNA.4 ISCC cited specific language in Bristle that
determines what might constitute a human embryo: "capable of
* PhD Candidate, Allard School of Law, University of British Columbia.
1. Case C-364/13, Int'l Stem Cell Corp. v. Comptroller Gen. of Patents, Designs, and Trade

Marks, EU:C:2014:2451 (Dec. 18, 2014).
2. Id. "Parthenogenesis" is a term describing the reproduction from an ovum without
fertilization, a normal process in some invertebrates and lower plants.
3. "The first patent, GB0621068.6, entitled 'Parthenogenetic activation of oocytes for the
production of human embryonic stem cells,' covered both the methods for producing
pluripotent human stem cell lines from parthenogenetically-activated oocytes and the stem cell

lines. The second application GB0621069.4, entitled 'Synthetic cornea from retinal stem cells,'
-

lincluded claims to methods and 'product-by-process."' Aurora Plomer, Case C-364/13
Patentabilityof Embryonic Stem Cells and Parthenotes:Inherently Uncertain?, EuropIA LAw (Dec.
2
19, 2014), https://eutopialaw.com/2014/1 /1

9

/case-c-

364

13-patentability-of-embryonic-stem-

cells-and-parthenotes-inherently-uncertain/.
4. Id. More specifically, ISCC argued that the parthenogenetically-activated oocytes are
incapable of initiating the process of development of a human being due to the phenomenon of
genomic imprinting. Id. Confronted with research suggesting that these hurdles could be
successfully overcome by genetic engineering, ISCC amended the claims by introducing the
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commencing the process of development of a human being," to argue for a
narrow interpretation including only those organisms capable of leading to a
full human being, rather than a broad one which would also include
organisms capable of commencing such process but incapable of leading to a
full human being.s The Chancery Division (Patents Court) of the High
Court of Justice (England & Wales) decided that the appeal "raised a
question of considerable importance" with regard to the meaning of the
term "human embryos" in the Biotech Directive.6 Finally, the ECJ held that
in order to be classified as a "human embryo," a non-fertilized human ovum
must have the "inherent capacity" of developing into a human being.7
Because an unfertilized human ovum whose division and further
development have been stimulated by parthenogenesis lacks the "inherent
capacity" to develop into a human being, it is not a "human embryo" within
the meaning of the Directive, and stem cells derived from it are therefore
patentable.s Reasoning that the issues at stake are questions of fact
answerable with reference to the state of scientific knowledge at the time of
the decision, the ECJ allowed national courts to decide, on a case-by-case
basis, whether parthenotes, in the light of "current scientific knowledge,"
have the "inherent capacity" of developing into a human being and qualify
for patent protection.9
While some may attribute the ISCC ruling to economic globalization or a
fear of "brain drain," it may be understood in the context of the globalization
of law. This possibility raises two questions. First, did American laws and
policies on hESC research and patents have any impact on the ECJ's
decision? Second, how might legal globalization affect the Court's
application of the "inherency" test to unexamined or new biotech inventions
in the future?
Part II of this article will examine why American laws and policies on
hESC research and patents may have had an impact on the ECJ decision,
despite the lack of direct evidence of this impact. While the decision does
not fully converge with American policy and rulings with regard to hESC
research and patents, its partial lifting of the general ban on hESC patents
signals a progression towards the American jurisprudence on these matters.
Moreover, as Part II will explain, the possible impact of legal globalization
coincided with the ECJ's activist role to promote human rights in the EU by
paying equal regards to all provisions of the Charter of Fundamental
word "pluripotent" before "human stem cell line" to exclude any possibility of genetic
manipulation. Id.
5. Case C-34/10, Oliver Bristle v. Greenpeace e.V., 2011 E.C.R. 1-09821 (Oct. 18, 2011).
6. Int'l Stem Cell Corp v. Comptroller General of Patents [2013] EWHC 807 (Ch) (17 April
2013) at para 5.
7. Case C-364/13, Int'l Stem Cell Corp. v. Comptroller Gen. of Patents, Designs, and Trade
Marks, EU:C:2014:2451 (Dec. 18, 2014).
8. Id.

9. Id.
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Freedoms for the European Union and the European Convention on
Human Rights.
Part Ell will look towards the future by predicting how courts of various
EU member states will apply the "inherency test" to determine the
patentability of hESCs, and how the ECJ, in the era of legal globalization,
may apply this test to unexamined or new biotechnological inventions.
Although the ECJ does not dictate how its member states should apply the
test, how various states, including Sweden, Germany, and Austria, will
approach and apply it is very predictable. This Part will also explain why the
2014 decision may have revealed an interaction between civil law and
common law features in the era of globalization, and how the ECJ may
balance the interests of different parties as it applies the law to unexamined
or new biotech inventions.
II.

ISCC in the Context of Legal Globalization

The 2014 decision may be regarded as the result of economic
globalization or more specifically, the fear of brain drain on the part of the
EU. Indeed, the topic of brain drain emerged repeatedly as the EU and the
U.S. revised their policies and laws with regard to stem cell research. For
example, the 2006 agreement among science ministers to allow part of the
Union's expanded budget to be spent on hESC research led to the
prediction that American scientists, dissatisfied with President George W.
Bush's restrictive policy on hESC research, would flock to Europe.o
President Obama's 2009 Executive Order boosting domestic stem cell
research funding likewise sparked fears among the European research
community of a possible brain drain across the Atlantic in the opposite
direction." Reactions among European scientists to the Bristle ruling were
especially gloomy.12

The impacts of these policies and laws nonetheless have been
overestimated. Critics noted that the interpretation of Brustle was
unnecessarily gloomy.13 First, because the Directive did not prohibit all
stem cell research, it neither "prevented European firms developing
technology platforms based on non-embryonic human stem cells nor has it
precipitated a 'brain-drain' of European stem cell expertise to the US or
Asia."14 In addition, despite prior patent restrictions, firms that develop and
sell human embryonic stem cell lines and their accompanying technology
10. Nicholas Watt, US Faces Science Brain Drain After Europe Backs Stem Cell Funding, THE
2
(July 25, 2009), https://www.theguardian.com/world/2006/jul/ 5/eu.genetics.
11. Ian Sample, Obama to Lift Restrictions on FundingStem Cell Research, THE GUARDiAN (Mar.
8, 2009), https://www.theguardian.com/science/2009/mar/09/stem-cell-research-lift-us-ban.
12. Emma, European Court Bans Stem Cell Patents, EURoSTEMCELL (Oct. 18, 2011), http://
www.eurostemcell.org/story/european-court-bans-stem-cell-patents.
13. Watt, supra note 10.
14. Michael Morrison, The Patenting of Human Embryonic Stem Cells, ESRC GENoMIcs
2 5326
NETWORK (Nov. 21, 2011), http://www.genomicsnetwork.ac.uk/egenis/news/
.

GUARDIAN
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platforms have flourished and remained competitive.15 Without denying the
role of economics, this article examines whether legal globalization may also
have played a role in the ISCC ruling.

A. WHAT

IS LEGAL/JUDICIAL GLOBALIZATION?

Because of globalization, legal problems tend to arise in similar ways,
especially in advanced societies and economies, including the U.S., the EU,
Canada, and Japan.16 National governments frequently look to their peers
for solutions to these problems, leading to the convergence of national
laws.17 Judicial globalization, or judicial interaction across borders, is one
source of this convergence.18 It takes place either "vertically" between
national and international tribunals, or "horizontally" across national
boundaries, as the need for judicial cooperation in resolving transnational
disputes has become more common.19
While processes like dispute resolution represent the most active types of
judicial interaction, "cross-fertilization" of national judicial decisions is a
common, more passive form of judicial globalization.20 Judges use foreign
law to support their arguments or legal reasoning, often without citation.21
The U.S. Supreme Court in particular, which almost never quotes other
courts, is itself the most quoted among foreign courts due to its rich supply
of ideas.22 Because "[c]ourts don't do what they say and they don't say what
they do," the use of foreign case law in different ways-both direct and more
subtle-is likely more frequent than it seems to be.23

B. THE

AMERICAN JURISPRUDENCE ON

HESC

RESEARCH AND

PATENT

American law and its judiciary possibly had an impact on the ECJ's
decision. One should note that hESC research and patentability in the U.S.
were first approved through legislation. The U.S. Patent Act holds that
15. Id.
16. See, e.g., Ralf Michaels, Globalization and Law: Law Beyond the State, DuKE LAW
SCHOLARSH[P REPOSITORY (Jan. 2013), http://scholarship.law.duke.edu/faculty-scholarship/

2862.
17. See, e.g., id.
18. Anne-Marie Slaughter, Judicial Globalization, 40 VA. J. INT'L L. 1103, 1103-04 (2000).
19. Id. at 1112.
20. Id. at 1116-19.
21. Marta Cartabia & Sabino Cassese, How Judges Think in a Globalised World? European and
American Perspectives, GLOBAL GOVERNANCE PROGRAMME, at 1, 3 (Dec. 2013). Judicial
networks have been established by the European legislature (EJN - European Judicial Network)
as well as by judiciaries themselves, such as the conference of European Constitutional Courts
and the International Association of Supreme Administrative Jurisdictions. Id. at 4-5. Academic
institutions also set up forums where judges and academics meet in order to create bridges
between research and practice. Id.
22. Id.
23. Id. at 4.

20171
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"[w]hoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor, subject to the conditions and
requirements of this title."24 This broad grant was limited by a few judicially
recognized exceptions, namely, "laws of nature, natural phenomena, and
abstract ideas."25 Later, the Supreme Court in Diamond v. Chakrabartyruled
that bioengineered living organisms were altered enough to deserve patent
protection.26 Following the Chakrabarty decision, the U.S. Patent and
Trademark Office (USPTO) wrestled with the question of the patentability
of other emerging forms of biotechnology, including those that are humanrelated. Its 1987 "Quigg Memo" considers that "[a] claim directed to or
including within its scope a human being will not be considered patentable
subject matter under 35 USC 101."27 Notwithstanding this longstanding
policy against the patenting of "entire" or "complete" human beings, the
USPTO has allowed for patents on "living tissue, genetically modified cells,
and other emerging forms of biotechnology," such as isolated human
2
genes. 8

With regard to hESC research, Congress banned the creation or
destruction of human embryos for research purposes in 1996, and President
George Bush signed an order in 2001 barring the National Institutes of
Health from funding research on embryonic stem cells beyond using the
sixty cell lines already in existence.29 Nevertheless, President Obama's
Executive Order 13,505 (2009), entitled "Removing Barriers to Responsible
Scientific Research Involving Human Stem Cells," repealed Bush's order by
casting such research as not ethically problematic.30 More recently, the
America Invents Act (AIA) of 2011 imposes a statutory limitation on
patentable subject matter through its § 33(a), stating that "no patent may
issue on a claim directed to or encompassing a human organism."31 The
24. 35 U.S.C § 101.
25. Alice Corp. Pty. Ltd. v. CLS Bank Int'l et al., 134 S.Ct. 2347, 2354-55 (2014).
26. Diamond v. Chakrabarty, 447 U.S. 303, 318 (1980).
27. Jonathan R. K. Stroud, Is Congress PoliticizingPatents?PatentingBiotechnology in the Wake of
Section 33, Prometheus, and CLS Bank, FOOD & DRUG POL'Y F. at 4 (July 25, 2012).
28. Id. at 2-3. "This policy was put to test in 1997, when scientist Stuart Newman sought to
obtain a patent for a human/non-human chimera," in part to force the USPTO to clarify its
policy regarding the patent eligibility of human organisms. Ava Caffarini, Directed to or
Encompassing a Human Organism: How Section 33 of the America Invents Act May Threaten the
Future of Biotechnology, 12

J. MARSHALL

REv.

INTELL.

PROP. L. 768, 776 (2013).

Although the

USPTO rejected Newman's patent application, stating that it would violate the Thirteenth
Amendment's ban on slavery and thus fail to meet the moral utility requirement under § 101, it
did not deal with the issue of the percentage of genetic material required to make a patent
application human-related.
29. Timeline of Major Events in Stem Cell Research Policy, RESEARCH AMERICA, http://www
.researchamerica.org/advocacy-action/issues-researchamerica-advocates/stem-cell-research/
timeline-major-events-stem-cell (last visited Aug. 14, 2015).
30. Exec. Order No. 13,505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
31. Leahy-Smith America Invents Act, PuB. L. No. 112-29 §33(a), 125 STAT. 284, 340
(codified as amended at 35 U.S.C. §101 (2011)).
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Congressional Record states that this amendment "simply reaffirms current
U.S. patent policy," that it "would not interfere in any way with any existing
patents with respect to stem cells," and that it would "not forbid funding
research on embryonic stem cells, because a human embryo is an 'organism'
but a stem cell clearly is not."32 The USPTO also issued a memorandum
stating that it viewed the amendment as "fully consistent with USPTO's
policy on the non-patentabiliy of human life-forms."3s Hence, § 33(a)
codifies the already existing policy by narrowly tailoring the patent exception
to only very rare circumstances, such as attempts to patent entire human
clones or human offspring for unethical, unsafe, or unconstitutional
purposes.
The legality of hESC research and patents has not been challenged by the
judiciary. In early 2013, the Supreme Court refused to step into the heated
debate over hESC research by declining to hear Sherley v. Sebelius, in which
two scientists challenged Obama's 2009 order.34 This lawsuit first arose in
2010, when James Sherley of the Boston Biomedical Research Institute and
Theresa Deisher of Sound Choice Pharmaceutical Institute sued on behalf
of "plaintiff embryos," alleging that Congress had forbidden hESC research
in 1996.35 When the Court of Appeals for the Federal Circuit upheld the
lower court's decision ruling that the National Institutes of Health could
legally fund hESC research, plaintiffs appealed to the Supreme Court.36
The Supreme Court's refusal to hear the case, though cannot be taken as its
support for Obama's order, allowed hESC research and patents to stay
ethical. Most recently, in Consumer Watchdog vs. Wisconsin Alumni Research
Foundation (2014), the Federal Circuit rejected Consumer Watchdog's
attempt to strike down a long-contested hESC patent held by the Wisconsin
Alumni Research Foundation, by holding that Consumer Watchdog lacked
standing to challenge the patent. 37 In February 2015, the Supreme Court
32. Stroud, supra note 27, at 4 (quoting 157 CONG. REc. El, 177-80 (daily ed. June 23, 2011)
(statement of Rep. Smith)).
33. Id. (quoting Memorandum from Robert W. Bahr, Senior Patent Counsel & Acting Assoc.
Comm'r for Patent Examination Policy to Patent Examining Corps (Sept. 20, 2011), available at
http://www.uspto.gov/aia-implementation/human-organism-memo.pdf.
34. Terry Baynes, U.S. High Court Won't Review FederalEmbryonic Stem Cell Funds, REUTERS
Gan. 7, 2013), http://www.reuters.com/article/us-usa-court-stemcell-idUSBRE9060IQ201301
07.
35. Id.
36. Id.
37. Consumer Watchdog v. Wis. Alumni Research Found., 753 F.3d 1258, 1263 (Fed. Cir.
2014); see Donald Zuhn, Consumer Watchdog v. Wisconsin Alumni Research Foundation (Fed. Cir.
2014), PATENTDOCS.ORG (June 5, 2014), http://www.patentdocs.org/2014/06/consumer-watch
dog-v-wisconsin-alumni-research-foundation-fed-cir-2014.html. This case lasted for over eight
years. In July 2006, Consumer Watchdog (CW) (then known as the Foundation for Taxpayer
and Consumer Rights), along with the Public Patent Foundation, filed formal requests with the
USPTO to revoke three patents held by Wisconsin Alumni Research Foundation (WARF), on
the grounds that they are overreaching and "significantly undermine research and waste
taxpayer money." When the USPTO upheld the challenges for all three stem cell patents in
2007, agreeing with CW's claim that WARF's work was "obvious in light of previous scientific
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denied Consumer Watchdog's petition to overturn the circuit ruling.38 This
decision, which does not examine whether hESCs are patentable, similarly
left the legality of hESC research and patent intact. Meanwhile, although
human stem cell patents in general do not go unchallenged, their
patentability has earned support from the USPTO and the judiciary where
the products are not naturally occurring.39
C.

Tim ECJ, JUDIcIAL AcTrvisM,

AND

HuMAN

RIGHTS

Decisions of the ECJ in general "[o]ffer no direct clue as to whether they
have been influenced by decisions of the U.S. Supreme Court" or any other
foreign court.40 Nevertheless, in certain important cases, the opinions of the
Advocates General have made references to the Supreme Court, which then
bore direct relevance to the ECJ decisions; alternatively, these references
may have a dialectic function where the ECJ did not follow the AG's
opinions.41 For example, in Netherlands v. Parliament & Council, the
Netherlands brought an action for annulment of the Biotech Directive.42
AG Francis Jacobs cited Diamond v. Chakrabarty to assure that the Biotech
Directive would "leave untouched" the "[c]lassic requirements for a patent
of novelty, inventive step, and industrial application," thus quenching the
anxiety that "[a]ny gene or gene sequence, or even the entire human
genome" would "automatically be patented."43 This opinion likely had a
heavy influence on the ECJ, which finally ruled in favor of the defendant by
research," WARF narrowed its patent claims to only include stem cells derived from "preimplantation embryos," which were eventually granted by USPTO in 2008 for all three patents.
In 2008, CW filed an appeal to the USPTO regarding the '913 patent. In 2013, it further filed
an appeal with the U.S. Federal Circuit to overturn USPTO's decision to uphold the '913
patent. On January 17, 2014, the USPTO responded to a request by the Federal Circuit panel
concerning CWs standing, arguing that CW had no actual standing to appeal its decision to
uphold WARF's patent as CW lacked any "concrete or particularized interest" in the issue at
hand and failed to show any "injury or harm" to justify an appeal. Further, CW argued that the
federal court did not satisfy the requirements for jurisdiction as specified by Article m of the
U.S. Constitution and therefore had no judicial power to render judgment.
38. David Jensen, California'sConsumer Watchdog Loses U.S. Supreme Court Challenge to WARF
Stem Cell Patents, CAL. STEM CELL REP. (Feb. 24, 2015), http://californiastemceUreport.blog
spot.ca/2015/02/californias-consumer-watchdog-loses-us.html.
39. For example, in Association of Molecular Pathology v. Myriad Genetics, the Supreme Court,
through a unanimous decision, held that while a naturally occurring DNA segment is a product
of nature and not patent eligible, a complementary DNA, or cDNA, which corresponds to the
naturally occurring DNA sequences except that certain of its non-coding sequences ("introns")
are removed, is not naturally occurring and therefore is patent eligible. Ass'n for Molecular
Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119 (2013).
40. Carl Baudenbacer, Judicial Globalization: New Development or Old Wine in New Bottles?, 38
TEx. INT'L LJ. 505, 516 (2003); see also Peter Herzog, United States Supreme Court Cases in the
Court ofJustice of the European Communities, 21 HAsTINGs INT'L & Comp. L. REv. 903 (1998).
41. See Baudenbacer, supra note 40, at 516.
42. Id. at 513.
43. Id.
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holding that the Directive was correctly adopted under Article 100a of the
E.C. Treaty (now Article 95 E.C.).44
Admittedly, there is no direct evidence as to whether the 2014 ruling was
influenced by American law. Moreover, AG Cruz Villal6n did not mention
any American cases or statutes at all in his opinion. On the other hand, the
fact that the ECJ was heavily influenced by AGs' references to American law
in past decisions indicates that it may have considered American law and
court cases like Sherley. Although the ECJ decision does not fully converge
with American policy and rulings, its partial lifting of the general ban on
hESC patents indicates its progression towards the American jurisprudence
on hESC research and patents.
Yet judicial globalization may have had a more indirect impact on the ECJ
decision, which went hand in hand with its effort to further its role in
championing human rights in the EU. Scholars have noted how the ECJ has
embraced the Supreme Court's role in the nationalization of American
politics in its own contribution to the EU's integration through judicial
activism. For example, Elizabeth F. Defeis notes that throughout its fifty
year history, the ECJ has held in a series of cases that fundamental rights of
individuals such as non-discrimination, freedom of religion, association, and
expression, were enshrined in the general principles of its Community law.4s
It has also incorporated provisions of the European Convention on Human
Rights (ECHR), decisions of the European Court of Human Rights, and the
Charter of Fundamental Rights of the European Union into its human
rights jurisprudence, noting that the principle aim of the Charter is to
reaffirm rights as they result from constitutional traditions and international
obligations common to Member States, the Treaty on the European Union,
and the ECHR.46
Whether in the U.S. or in Europe, hESC research and biotechnology in
general have sparked fears that such innovations violate the sanctity of
human life.47 Further, hESC patents raise concerns that patients' access to

the patented inventions will be limited by high costs as a consequence of
monopolies.48 But the right to conduct research and intellectual property
rights are also derived from basic human rights. The American legislature
and courts, by allowing patents except those encompassing human
organisms, have striven to balance the right to conduct research and to own
intellectual property with the sanctity of human rights and the right to
44. Id.
45. Elizabeth F. Defeis, Human Rights and the European Court of Justice: An Appraisal, 31
FoRDHAms NT'L L.J. 1104, 1110 (2008).
46. Id. at 1110-11; see also Case C-540/3, European Parliament v. Council of the European
Union, 2006 E.C.R 1-5769.
47. See, e.g., Jessica Reaves, The Great Debate Over Stem Cell Research, TmE (July 11, 2001),
http://content.time.com/time/nation/article/0,8599,167245,00.html; Human Embryonic Stem
Cell Research and Ethics, EUROSTEMCELL (Mar. 4, 2011), http://www.eurostemcell.org/files/
Human _ESethics 1.pdf.
48. See, e.g., Reaves, supra note 47.
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access patented inventions. In contrast, until its 2014 ruling, the ECJ had
not struck a similar balance. While the ECHR mentions neither human
dignity nor intellectual property, Article 1 of its Protocol states that "[e]very
natural or legal person is entitled to the peaceful enjoyment of his
possessions."49 The Charter more directly addresses these issues. Although
Article 1 states that human dignity is to be safeguarded, and Article 3
prohibits eugenic practices and human cloning, Article 17 safeguards the
right to intellectual property.50 By lifting part of its general ban on
obtaining patents for hESCs in ISCC, the ECJ thus addressed and
accommodated the right to conduct hECS research and patenting the
products of such research by balancing it with the right to access new
inventions and the dignity of human life.

II.

Legal Globalization and the Likely Applications of the

"Inherency" Test
Critics predict that national patent offices and courts will react differently
to the ECJ decision.5' Although it empowered national courts to decide
whether parthenotes have the "inherent capacity to develop into a human
being," it did not provide proper guidelines for the "inherency" test. As AG
Villal6n stated, Member States might still decide to ban the patenting of
hESCs derived from human parthenotes in accordance with the more
general exclusion in Article 6 (1) of the Biotech Directive on the grounds of
public order and morality.52 In light of the different positions of Member

States regarding the definitions of embryo and stem cell research, this
discretion may lead to uncertainty. Further, one wonders whether a stored
frozen human embryo has the inherent capacity to become a human being if
it is never going to be implanted.53 This section thus predicts how courts of
various Member States will apply the "inherency test," and how the ECJ
may apply this test to unexamined or new biotech inventions.
49. European Convention on Human Rights, art. 1, Sept. 3, 1953, E.T.S. No. 005.
50. Charter of FundamentalRights of the European Union art. 1, 3, 17, 2010 0J. C 83/02.
51. Timo Minssen & AnaNordberg, The Evolution of the CJEUs Case Law on Stem Cell Patents:
Context, Outcome and Implications of Case C364/13 InternationalStem Cell Corporation, 5 NoRvic
IwTELL. PROP. L. J. 493, 502 (2015). First, it remains unclear how the European Patent Office
will react and how national patent offices will interpret the present decision in practice. The
EPO, which is not an EU institution, is not formally bound by the Biotech Directive, nor is it
obliged to accept the decisions of the CJEU. But, its Administrative Council introduced in
September 1999 several of the relevant provisions of the Biotech Directive into the
Implementing Regulations to the EPC (the "Rules"). For the sake of harmonization, it will
likely mirror the ISCC decision in its guidelines for examination and implemented in its
practice, which was the approach taken following the Briistle decision.
52. Opinion of Advocate General Villal6n, Case C-364/13, Int'1 Stem Cell Corp. v.
Comptroller Gen. of Patents, Designs, and Trade Marks, EU:C:2014:2014 (Dec. 18, 2014).
53. Aurora Plomer, Case C-364/13 - Patentability of Embryonic Stem Cells and Parthenotes:
Inherently Uncertain?, EuToPIA LAw (Dec. 19, 2014), https://eutopialaw.com/2014/12/19/casec-36413-patentability-of-embryonic-stem-cells-and-parthenotes-inherently-uncertain/.
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PREDICTING MEMBER STATES' NEw POLICIES ON HESC
PATENTING

The hESC regulatory regimes in the EU countries are highly disparate.
On the restrictive end, Germany prohibits embryo research and makes the
importation of stem cell lines from other nations subject to a cut-off date.54
Austria prohibits the procurement of cells from a human embryo for
research purposes, but allows the use of pluripotent embryonic stem cells
(which are capable of developing into any type of cell or tissue except those
that form a placenta or embryo) that have already been established in a
lawful manner, for example, in other nations, or outside the territorial scope
of its law.ss Similarly, Italy bans the derivation of hESC lines, but permits
the use of imported ones for research.56 On the more permissive end,
France allows hESC research so long as specific conditions are met.57
Portugal allows stem cell research and permits the use of frozen or surplus
embryos created in-vitro for the derivation of hESC lines that would bring
therapeutic and medical benefits to the community.ss The U.K. and Sweden
have remained the most aggressive promoters of hESC research: while
forbidding reproductive cloning, both have comprehensive and wellestablished regulatory frameworks for stem cell research, and allow the use
of IVF embryos, the destruction of these embryos to find new stem lines,
and the creation of embryos through somatic cell nuclear transfer.s9
The responses of national courts to the ISCC ruling are not difficult to
predict. Because Germany permits no hESC research at all, it will not allow
the patenting of hESCs, including those derived from parthenotes. Austria
and Italy, which permit the use of imported hESC lines for research, will
more likely than not permit the patenting of hESC research output derived
from parthenotes. First, parthenotes lack the "inherent capacity" to develop
into a human being according to current scientific knowledge in these two
54. Regulation of Stem Cell Research in Germany, EuRoSTEMCELL (Mar. 1, 2012), http://www
.eurostemcell.org/regulations/regulation-stem-cell-research-germany.
55. Regulation of Stem Cell Research in Austria, EuRoSTEMCELL (June 18, 2013), http://www
.eurostemcell.org/regulations/regulation-stem-cell-research-austria.
56. Regulation of Stem Cell Research in Italy, EuioSTEMCELL (Mar. 1, 2012), http://www
.eurostemcell.org/regulations/regulation-stem-cell-research-italy.
57. Regulation of Stem Cell Research in France, EUROSTEMCELL (Mar. 1, 2012), http://www
.eurostemcell.org/regulations/regulation-stem-cell-research-france. The research must meet
all four conditions: it is scientifically relevant; it is likely to allow major medical advances; it
cannot be performed unless cells derived from embryos are used; it respects French ethical
principles for research on embryos and embryonic stem cell lines. Embryos used for research
must come from the assisted reproduction process (IVF) and informed consent must be
obtained from the donors. Id.
58. Regulation of Stem Cell Research in Portugal, EuRoSTFMCELL (Dec. 1, 2011), http://www
.eurostemcell.org/regulations/regulation-stem-cell-research-portugal.
59. Regulation of Stem Cell Research in the United Kingdom, EuRoSTEmCELL (Dec. 14, 2011),
http://www.eurostemcell.org/regulations/regulation-stem-cell-research-united-kingdom;
Regulation of Stem Cell Research in Sweden, EuRoSTEMCELL (Mar. 1, 2012), http://www.euro

stemcell.org/regulations/regulation-stem-cell-research-united-kingdom.
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nations. Second, these two nations have legalized abortion since 1974 and
1978 respectively,60 and therefore have little reason to prohibit, on the
grounds of public order and morality, patenting hESCs made from
unfertilized cells that have not even achieved the "embryo" status. Because
France and Portugal allow hESC research under certain conditions, they will
likely allow the patenting of parthenote-derived hESCs that are lawfully
produced under these conditions. Finally, the U.K. and Sweden, both with
progressive policies, will find no justification in banning hESC research and
patents.
B.

THE

"INHERENCY" TEST AND UNEXAMINED AND

NEW

BIOTECH

INVENTIONS

The question concerning the application of the "inherency" test to
unexamined and new biotech inventions is more difficult to answer. Because
the 2014 decision possibly revealed an interaction between civil and
common law features in the era of globalization, legal globalization provides
a framework for predicting how the ECJ may apply the "inherency" test to
these inventions.
Scholars have attempted to lay out the major aspects of civil law and
common law models as reflected in the EU and the U.S. legal systems
respectively. For example, Charles H. Koch points out that the EU legal
principles are largely founded upon the civil law model, the codes of which
are the product of the "Age of Reason" and premised on the belief that life
has an order.61 The drive for certainty and stability "emphasizes systemic
values focusing on definitions and categorizations."62 Such an emphasis on
categorization is often criticized as "insensitive" and "static" by U.S.
commentators whose modem jurisprudence focuses on balancing rather
than categorization: "Balancing requires the explicit articulation and
comparison of rights or structural provisions, modes of infringement, and
government interests."63

Nevertheless,

one needs to consider that the

principle of proportionality originated in continental Europe and is one of
the fundamental principles of the jurisprudence developed by the ECJ. In
60. See Bundesgesetz vom 23. Jinner 1974 fiber die mit gerichtlicher Strafe bedrohten
Handlungen (Strafgesetzbuch [StGB]) [Federal Law of 23 January 1974 on Punishable Acts
(Penal Code [StGB]) (in force on Jan. 1, 1975, as last amended by Bundesgesetzblatt [BGBl] I
No. 106/214, Dec. 29, 2014, Part I, No. 1974/60, Stick 21, pp. 641-92 (Austria) (available in
English at http://www.hsph.harvard.edu/population/abortion/Austria.abo.htm); Termination of
Pregnancy and Abortion in Italy, ANGLOINFO, http://rome.angloinfo.com/information/health
care/pregnancy-birth/ternination
61. Charles H. Koch, Jr., Envisioninga GlobalLegalCulture, 25 WhCH. J. INT'L L. 1, 10 (2003).
62. Id. at 17-18.
63. Id. at 44.
64. The proportionality principle, according to which a public authority may not impose
obligations on a citizen except to the extent to which they are strictly necessary in the public
interest to attain the purpose of the measure, is the preferred procedure for managing disputes
involving an alleged conflict between two rights claims, between a rights provision and a state or
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addition, because the civil system by no means prohibits change, its
categorization is an applied-not extreme-formalism that allows for certain
degrees of creativity in interpretations and applications, especially in the age
of globalization.65
Despite using the case law method, the ECJ was established in principle
on civil law principles. Hence its rulings resemble interpretative decisions
by civil law courts more than creative ones by common law courts.66
Because the ISCC ruling made no reference to the proportionality principle,
it arguably contained an implicit balancing of rights and interests that
possibly revealed the influences of the common law principles. By tapping
into the ambiguity of Bruistle's criterion of a human embryo as one that is
"[c]apable of commencing the process of development of a human being,"
ISCC pointed out, first, that there exist two interpretations, and second, that
its narrow interpretation is preferable to its broad interpretation.67 AG
Villal6n and the ECJ did not expressly conduct such a comparison. But AG
Villal6n impliedly endorsed ISCC's logic and argument for the narrow
interpretation by redefining "human embryo" as necessarily containing the
"inherent capacity" of developing into a human being.68 The ECJ did the
same by following the AG's opinion. By refusing to strictly adhere to the
definition in Bristle, and by implicitly assessing two interpretations, the ECJ
balanced the rights to intellectual property and to conduct research with
respect for human dignity and the right to access inventions.
Recent technological advances may complicate the application of the
"inherency" test. Scholars have mentioned, for example, the generation of
hESCs from "non-viable"69 "triploid zygotes":70 arising in approximately 5%
of in-vitro fertilizations (IVF), these contain an extra set of haploid
chromosomes of which prevent them from developing to term. 71 Another
example would be the patentability of blastocysts created by abnormal
nuclear transfer, which cannot be implanted into the uterus but are capable
public interest (constitutional law), or between a private interest and a state or public interest
(administrative law). This principle originated in continental (in particular German)
administrative law, but is also connected to the new wave of (liberal) constitutionalism that has
spread worldwide since the Second World War. Tor-Inge Harbo, The Function of the
ProportionalityPrinciple in EU Law, 16 EuROPEAN L. J. 158, 158 (2010).
65. See Koch, supra note 61, at 18.
66. See, e.g., id. at 38; Anita Frohlich, The European Union as a Mixed Legal System,
COMPARELEX (June 5, 2014), https://comparelex.org/2014/06/05/the-european-union-as-amixed-legal-sytem/.
67. Case C-34/10, Oliver Bristle v. Greenpeace e.V., 2011 E.C.R. 1-09821 (Oct. 18, 2011).
68. See Opinion of Advocate General Villal6n, Case C-364/13, Int'l Stem Cell Corp. v.
Comptroller Gen. of Patents, Designs, and Trade Marks, EU:C:2014:2014 (Dec. 18, 2014).
69. "Viability" refers to the potential to develop through gestation to birth.
70. Organisms whose cells contain a distinct membrane-bound nucleus, and are formed by
fertilization between two gametes and containing three homologous sets of chromosomes.
71. Gerard Porter, Chris Denning, Aurora Plomer, John Sinden & Paul Torremans, The
Patentability of Human Embryonic Stem Cells in Europe, 24 NATURE BIOTECHNOLOGY 653, 655
(2006).
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of generating customized embryonic stem cells.72 One further example
would be hESCs created by using a discarded ITVF supernumerary, which is a
fertilized egg. 73
How would the ECJ apply the "inherency" test to unexamined or new
biotech inventions? Where fertilized cells, such as non-viable triploid
zygotes and blastocysts are involved, the European Patent Office and the
ECJ would need to consider whether viability is a necessary condition for
the cells to be classified as an "embryo." This leads to two options: Either
viability is a necessary condition for the inherency test, or it is not. Given
current scientific development-neither non-viable triploid zygotes nor
blastocysts created by abnormal nuclear transfer can develop into human
beings-the ECJ would likely consider viability to be a necessary condition
for the "inherency" test. Thus, it would likely consider hESCs derived from
both types of cells to be patentable. The ECJ could also achieve this result
by assessing and balancing the rights of different parties: because the
fertilized cells cannot develop into human beings and therefore cannot be
said to have human dignity, the right to claim property in hESCs derived
from these new inventions would win the balance of these rights.
What about the use of a discarded IVF (in vitro-fertilized)
supernumerary-a fertilized egg-to create hESCs?74 Because this method
involves a viable fertilized egg, which would pass the inherency test, hESCs
created through this method should not be patentable. Yet a further
complication may occur because among these fertilized eggs, or preembryos that are in deep freeze, some of the post-thaw pre-embryos may be
deemed "unviable" and thus lacking the inherent capacity of developing into
a human being.75 The ECJ may then consider the interests of various parties
and adjust the balance as it applies the law to different scenarios.
IV.

Conclusion

This article has explained how legal globalization provides a framework to
understand the ECJ ruling in ISCC. America's laws and policies on hESC
research and patents may have had some impact on the ECJ decision, an
impact that went hand in hand with the Court's activist role in its promotion
of human rights in the EU. In the future, the ECJ may need to apply the
"inherency" test to unexamined or new biotech inventions. It would likely
72. Id. Blastocysts are structures formed in the early development of mammals. They possess
an inner cell mass that subsequently becomes the embryo.
73. E.g., Anna Nordberg & Timo Minssen, A "Ray of Hope" for European Stem Cell Patents or
"Out of the Smog into the Fog"?An Analysis of Recent European Case Law and How It Compares to the
US, 47 INT'L REv. INTELL. PROP. AND COMPErITION L. 138, 138 n. 24 (2016).
74. E.g., Stem Cell Research, UNIv. oF MICH., http://www.stemcellresearch.umich.edu/over
view/faq.html (last visited Oct. 7, 2016).
75. E.g., Embryo & Blastocyst Grading: Which to Transfer, Which to Discard, SIER FERTILITY,
http://haveababy.com/fertility-information/ivf-authority/embryo-blastocyst-grading-which-totransfer-which-to-discard (last visited Oct. 7, 2016).
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adopt a mixed, creative approach towards these inventions, which may reveal
the influences of common law influences upon civil law traditions in the era
of globalization.

